Simard, Jean-Christophe, Thibodeau, Jean-François, Leduc, Martin, Tremblay, Mikael, Laverdure, Alexandre, Sarra-Bournet, Francois, Gagnon, William, Ouboudinar, Jugurtha, Gervais, Liette, Felton, Alexandra, Letourneau, Sylvie, Geerts, Lilianne, Cloutier, Marie-Pier, Hince, Kathy, Corpuz, Ramon, Blais, Alexandra, Marques Quintela, Vanessa, Duceppe, Jean-Simon, Abbott, Shaun D, Blais, Amélie, Zacharie, Boulos, Laurin, Pierre, Laplante, Steven ORCID: https://orcid.org/0000-0003-2835-5789, Kennedy, Christopher R J, Hébert, Richard L, Leblond, François A., Grouix, Brigitte et Gagnon, Lyne
(2020).
Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease
Scientific Reports
, vol. 10
, nº 12778.
p. 1-16.
DOI: 10.1038/s41598-020-69675-8.
Prévisualisation |
PDF
- Version publiée
Disponible sous licence Creative Commons Attribution. Télécharger (11MB) | Prévisualisation |
Résumé
Non-alcoholic Fatty Liver Disease (NAFLD) is the most common form of liver disease and is associated with metabolic dysregulation. Although G protein-coupled receptor 84 (GPR84) has been associated with inflammation, its role in metabolic regulation remains elusive. The aim of our study was to evaluate the potential of PBI-4547 for the treatment of NAFLD and to validate the role of its main target receptor, GPR84. We report that PBI-4547 is a fatty acid mimetic, acting concomitantly as a GPR84 antagonist and GPR40/GPR120 agonist. In a mouse model of diet-induced obesity, PBI-4547 treatment improved metabolic dysregulation, reduced hepatic steatosis, ballooning and NAFLD score. PBI-4547 stimulated fatty acid oxidation and induced gene expression of mitochondrial uncoupling proteins in the liver. Liver metabolomics revealed that PBI-4547 improved metabolic dysregulation induced by a high-fat diet regimen. In Gpr84(-/-) mice, PBI-4547 treatment failed to improve various key NAFLD-associated parameters, as was observed in wildtype littermates. Taken together, these results highlight a detrimental role for the GPR84 receptor in the context of meta-inflammation and suggest that GPR84 antagonism via PBI-4547 may reflect a novel treatment approach for NAFLD and its related complications.
Type de document: | Article |
---|---|
Mots-clés libres: | - |
Centre: | Centre INRS-Institut Armand Frappier |
Date de dépôt: | 22 juill. 2021 21:36 |
Dernière modification: | 15 févr. 2022 18:48 |
URI: | https://espace.inrs.ca/id/eprint/11687 |
Actions (Identification requise)
![]() |
Modifier la notice |